Global HIV and COVID-19 Emergency Response Fund

Global HIV and COVID-19 Emergency Response Fund

On April 27, 2020, ViiV Healthcare announced the creation of £3-million Global HIV and COVID-19 Emergency Response Fund to provide financial resources to study the medical and scientific impact COVID-19 on people living with HIV and community-based grants to help address specific challenges in the HIV community created by the global pandemic.

The ViiV Healthcare Global HIV and COVID-19 Emergency Response Fund will be divided equally between two programs. One, the Research Emergency Response Fund, will provide up to £1.5 million to support scientific research about the impact of COVID-19 on people living with HIV. ViiV Healthcare is inviting research proposals in three priority areas of interest: epidemiology and real-world data; healthcare systems management initiatives in COVID-19 environments; and biomarkers indicative of disease susceptibility, severity, and progression.

The other program, the Community Emergency Response Fund, will provide up to £1.5 million to support community-based activities addressing the specific challenges faced by people living with HIV during the COVID-19 pandemic. Grants will support ongoing access to critical HIV prevention, care and outreach services, short term payments for critical community staff, and community monitoring and feedback on the impact of COVID-19 on HIV services and support.

Deborah Waterhouse, CEO at ViiV Healthcare, said in a press release, “Our mission is to leave no person living with HIV behind and in these unprecedented times, it’s more important than ever that we use our resources and expertise to do just that…

Through this fund, we can support research about the impact of COVID-19 on people living with HIV that is urgently needed. We will also be able to provide support to local community organizations who are grounded in the response to the pandemic and those who have been impacted by COVID-19 to allow them to continue the important work they are doing to support the HIV community. We know their support of the broader health system will help save lives.”

ViiV Healthcare is a global specialist HIV company, established in November 2009 by GlaxoSmithKline and Pfizer, dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV.


Interested applicants can log on to www.covid-19rfp.viivhealthcare.com for proposal materials and additional information on eligibility and how to apply. For more information on ViiV Healthcare, visit www.viivhealthcare.com.

—Reporting by Hank Trout


Hank Trout, Senior Editor, edited Drummer, Malebox, and Folsom magazines in the early 1980s. A long-term survivor of HIV/AIDS (diagnosed in 1989), he is a forty-year resident of San Francisco, where he lives with his husband Rick. Follow him on Twitter @HankTroutWriter.